VDYNE's Heart Valve Trial Targets Neglected Tricuspid Disease

MAPLE GROVE, MN – April 01, 2026 – VDYNE, Inc., a Minnesota-based medical device company, has received a critical green light from the U.S. Food & Drug Administration (FDA) to begin a pivotal clinical trial for its novel transcatheter tricuspid valve replacement (TTVR) system. The approval of an Investigational Device Exemption (IDE) allows the company to launch the TRIVITA1 study, a decisive step toward bringing a new, minimally invasive solution to patients suffering from severe tricuspid regurgitation (TR), a debilitating and often overlooked heart condition.

This regulatory milestone moves VDYNE into the final stages of clinical validation in the United States, positioning the company to generate the safety and effectiveness data required for potential market approval. The trial will enroll patients at leading clinical centers to evaluate the VDYNE system in a real-world setting.

“This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,” said Mike Buck, the company's Chief Executive Officer, in a statement. “Our focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.”

A New Hope for the 'Forgotten Valve'

Tricuspid regurgitation occurs when the tricuspid valve, which separates the right atrium and right ventricle of the heart, fails to close properly. This leak causes blood to flow backward, increasing pressure in the right side of the heart and leading to symptoms like severe fatigue, fluid retention in the abdomen and legs, and shortness of breath. For decades, TR was often termed the “forgotten valve” disease, frequently overshadowed by issues affecting the left-sided mitral and aortic valves.

However, the clinical community now recognizes its severe impact. An estimated 1.6 million people in the U.S. live with moderate to severe TR. Left untreated, the condition is linked to a grim prognosis, with some studies showing one-year mortality rates as high as 23% for medically managed patients. Despite its prevalence and severity, treatment options have remained starkly limited.

Medical therapy, primarily using diuretics, can help manage symptoms but does not address the underlying valve defect. The only definitive treatment has been open-heart surgery to repair or replace the valve, an invasive procedure that carries significant risk, especially for the typically older and sicker patient population affected by TR. Consequently, a vast majority of patients are deemed ineligible for surgery, leaving them with a progressively worsening quality of life.

VDYNE’s TTVR system is designed to fill this therapeutic void. Delivered via a catheter, it offers a minimally invasive alternative to open-heart surgery, potentially providing a viable option for high-risk patients who currently have none.

Innovating in a Crowded Field

The race to develop effective transcatheter treatments for TR has intensified in recent years, transforming a once-neglected area of cardiology into a highly competitive market. VDYNE enters a dynamic field where major industry players have already made significant inroads.

In early 2024, the FDA approved two landmark devices: Abbott’s TriClip, a clip-based repair system that brings the valve leaflets closer together, and Edwards Lifesciences' EVOQUE, the first transcatheter valve replacement system to gain U.S. approval. These approvals marked a paradigm shift, establishing transcatheter therapy as a new standard of care for certain TR patients.

Against this backdrop, VDYNE aims to differentiate its technology through a unique, patient-tailored design. The VDYNE TTVR system features an asymmetric double-frame nitinol prosthesis housing a porcine tissue valve. This design is engineered to conform to the complex and non-circular anatomy of the native tricuspid annulus, aiming to minimize stress on the right ventricle. Its novel side-delivery mechanism allows a single-size catheter to deliver a wide range of valve sizes, simplifying the procedure.

Early clinical experience has been promising. Since its first-in-human use in November 2023, the system has been implanted successfully in patients through compassionate use programs and early feasibility studies, including the VISTA-US and VISTA-Global trials. Initial results have shown successful implantation and elimination of TR without major adverse events in the initial patient cohorts, providing crucial insights that have informed the design of the pivotal TRIVITA1 trial.

The Rigorous Path to Approval

Receiving IDE approval is a significant achievement, but it marks the beginning, not the end, of a long and rigorous regulatory journey. The TRIVITA1 pivotal trial is designed to provide the definitive evidence of the VDYNE system's safety and efficacy. Such trials for Class III devices, the FDA's highest-risk category, are complex and expensive undertakings that can take several years to complete.

Investigators in the trial will meticulously track patient outcomes, including reduction in TR, improvements in quality of life, heart failure hospitalizations, and procedural safety events like the need for a permanent pacemaker, which can be a complication in TTVR procedures. The data gathered will form the core of a Premarket Approval (PMA) application, the comprehensive submission required for the FDA to consider a device for commercial use.

VDYNE is not just developing a device; it is building a body of evidence. The company's success will depend on demonstrating a clear benefit-risk profile that convinces both regulators and the clinical community. This path has been paved by its competitors, whose clinical data and interactions with the FDA have helped define the endpoints and expectations for new therapies in this space.

Behind VDYNE is the Jean Boulle Group, a private investment entity with a proven track record in the medtech space. The group previously founded Tendyne, another transcatheter valve company that was successfully acquired by Abbott. This history suggests a strategic, long-term vision for VDYNE, backed by experienced investors who understand the pathway from innovation to market. The launch of a pivotal trial signals strong confidence in the technology and a firm commitment to navigating the demanding path to commercialization. As the TRIVITA1 trial begins enrollment, patients, clinicians, and investors will be watching closely to see if this innovative device can truly transform care for the heart’s forgotten valve.